Preclinical evaluation of [211At]At-AuNP-ABDMPL16 for targeted alpha therapy in Melanoma

• DOI: 10.1007/s00259-025-07238-7
• Publication Date: 2025-05-20T16:02:25Z
• Authors: Jiajia Zhang; Shanshan Qin; Xuhao Huang; Erina Hilmayanti; Fan Hu; Xiaohui Luan; Tianzhen Ye; Feize Li; Yuanyou Yang; Ning Liu; Kazuya Kabayama; Koichi Fukase; Fei Yu
• Keywords: Alpha (finance)

The aim of this study is to overcome the challenges poor tumor penetration and systemic toxicity in targeted alpha therapy (TAT) while also evaluating its immunomodulatory effects enhance antitumor immune responses melanoma treatment. This developed a 211At-labeled single-domain antibody agent ([211At]At-AuNP-ABDMPL16) targeting PD-L1, protein overexpressed cells. binding affinity internalization [211At]At-AuNP-ABDMPL16 were evaluated vitro using cell lines. In vivo studies melanoma-bearing mice conducted assess biodistribution, pharmacokinetics, therapeutic efficacy, response induced by demonstrated high efficient cells, resulting significant death through α-particle radiation. vivo, preferentially accumulated tumors, inhibited growth, prolonged survival mice. treatment triggered robust anti-tumor response, marked increased cytotoxic T lymphocytes reduced regulatory cells within microenvironment, with minimal toxicity. shows promise as novel for melanoma, combining effective potent immune-activating effects. These findings support further investigation antibodies clinical applications.